Are you over 18 and want to see adult content?
More Annotations
A complete backup of chetsfishingcharters.com
Are you over 18 and want to see adult content?
A complete backup of kaplankomputing.com
Are you over 18 and want to see adult content?
A complete backup of merchantsfoodservice.com
Are you over 18 and want to see adult content?
A complete backup of studentartguide.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of freight-masters.net
Are you over 18 and want to see adult content?
A complete backup of prensaregional.pe
Are you over 18 and want to see adult content?
A complete backup of offshorewind.biz
Are you over 18 and want to see adult content?
A complete backup of planetisuzoo.com
Are you over 18 and want to see adult content?
A complete backup of gamestracker.com
Are you over 18 and want to see adult content?
Text
THE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical DISCLOSURE OF PAYMENTS TO HCPS Disclosure of payments to HCPs. Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis UNLOCKING THE POTENTIAL OF THE EUROPEAN HEALTH DATA SPACE Managing a public health crisis effectively is not simply about controlling the spread of a virus. For people living with one or multiple chronic diseases, pandemics such as COVID-19 bring severe synergistic impacts, which require a more nuanced and comprehensive approach to how we manage diseases, particularly in times of crises. ACCELERATING ADOPTION OF COMPLEX CLINICAL TRIALS IN EUROPE Register. Complex Clinical Trials (CCTs) have the potential to accelerate drug development and enable patients to get timely access to transformative therapies. The main objective of this workshop is to develop shared solutions by: What is CCT – simplifying and standardising definition of CCT. Why CCTs – how CCT can acceleratedrug development.
IQVIA/EFPIA PIPELINE REVIEW 2021 IQVIA/EFPIA Pipeline Review 2021. This document contains a pipeline overview, deep dives of the eight areas, as well as considerations forinnovation access
NATHALIE MOLL
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for UNLOCKING THE POTENTIAL OF PRECISION MEDICINE IN EUROPE Advances in biomarker testing are having a transformative impact on cancer care, but Europe will have to overcome significant barriers in the equitable access and quality of these tests to realise their full potential, concludes an important new study released by the International Quality Network for Pathology (IQN Path), the European Cancer Patient Coalition (ECPC) and the European Federation EFPIA HOMEPAGECOVID-19 CHEVRON_RIGHTMANIFESTOCONTACT USKMS LOGINPATIENT ORGANISATIONSPATIENT STORIES Europe’s framework of incentives and rewards for discovering and developing new treatments deliver access to today’s medicines and investment into tomorrow’s cures for patients who need them. Only 8 OMP medicines existed in 2000, before the EU Regulation came in to force, compared to 184 today. EFPIA PATIENTS W.A.I.T. INDICATOR 2020 SURVEY 4 Full methodology and definitions by country are available within the appendix Study summary * The Patients W.A.I.T. Indicator is not a measurement of the delays as defined in the “Transparency” Directive (directive 89/105/EEC).Delays under the “Transparency” Directive reflect the EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world throughTHE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical DISCLOSURE OF PAYMENTS TO HCPS Disclosure of payments to HCPs. Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis UNLOCKING THE POTENTIAL OF THE EUROPEAN HEALTH DATA SPACE Managing a public health crisis effectively is not simply about controlling the spread of a virus. For people living with one or multiple chronic diseases, pandemics such as COVID-19 bring severe synergistic impacts, which require a more nuanced and comprehensive approach to how we manage diseases, particularly in times of crises. ACCELERATING ADOPTION OF COMPLEX CLINICAL TRIALS IN EUROPE Register. Complex Clinical Trials (CCTs) have the potential to accelerate drug development and enable patients to get timely access to transformative therapies. The main objective of this workshop is to develop shared solutions by: What is CCT – simplifying and standardising definition of CCT. Why CCTs – how CCT can acceleratedrug development.
IQVIA/EFPIA PIPELINE REVIEW 2021 IQVIA/EFPIA Pipeline Review 2021. This document contains a pipeline overview, deep dives of the eight areas, as well as considerations forinnovation access
NATHALIE MOLL
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for UNLOCKING THE POTENTIAL OF PRECISION MEDICINE IN EUROPE Advances in biomarker testing are having a transformative impact on cancer care, but Europe will have to overcome significant barriers in the equitable access and quality of these tests to realise their full potential, concludes an important new study released by the International Quality Network for Pathology (IQN Path), the European Cancer Patient Coalition (ECPC) and the European FederationTHE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical DISCLOSURE OF PAYMENTS TO HCPS Disclosure of payments to HCPs. Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis NEW ECIPE STUDY ON “INTERNATIONAL EU27 PHARMACEUTICAL New ECIPE study on “International EU27 pharmaceutical production, trade, dependencies and vulnerabilities” Faced with the COVID-19 pandemic, global supply chains have shown remarkable resilience, and open markets and open trade have been one of the key reasons behindthis.
INTELLECTUAL PROPERTY Intellectual property has the power to bring about vital medical innovation. It creates access to new treatments which in turn creates healthy populations. It can support people’s lives and their livelihoods. YouTube. EFPIA. 627 subscribers. PATIENT ORGANISATIONS Patient organisations. People should be at the heart of healthcare. From, prevention and awareness, through research and development, regulatory and Health Technology Assessment (HTA) processes, to service design and outcomes measurement. Patients bring invaluable knowledge and experience of living with a condition, while patient CANCER CARE IN EUROPE: WHERE ARE WE IN 2020? Among the key findings of the Comparator Report on Cancer in Europe 2020, is what looks like a paradox: although more people are being diagnosed with cancer, a smaller proportion of those people appear to be dying from the disease. The report, a comprehensive overview of major cancer trends across Europe, quickly unravels the mystery. EFPIA RESPONSE TO THE EU ROADMAP ON THE “EVALUATION AND Yesterday, EFPIA filed its response to the EU roadmap/IIA on the “Evaluation and revision of the general pharmaceutical legislation” containing proposed priorities for legislative change to equip the regulatory framework to respond quickly to the needs of patients across Europe.Speaking about the response, EFPIA Director General Nathalie Moll said: “The evaluation of the general FINAL CDEG RECOMMENDATION ON USE OF FORM FDA 1572 FOR 1 EFPIA CDEG position paper on the use of Form FDA 1572 for clinical trials performed outside the USA 14 January 2020 The EFPIA Clinical Development Expert Group (CDEG) was made aware that some EU THE PHARMACEUTICAL INDUSTRY IN FIGURES 7 PHARMACEUTICAL INDUSTRY RESEARCH AND DEVELOPMENT IN EUROPE EFPIA 2017 € million € million Austria 294 Belgium 3,508 Bulgaria n.a Croatia 40 Cyprus 85 Czech Rep. 77 Denmark 1,632 Estonia n.a Finland 201 France 4,451 Germany 6,918 Greece 42 Hungary 176 Iceland n.a Ireland 305 Italy 1,530 Latvia n.a Lithuania n.a Malta n.a Netherlands 642 Norway 126 Poland 340 EFPIA PATIENTS W.A.I.T. INDICATOR 2019 SURVEY The yearly EFPIA Patients WAIT survey, developed with the support of IQVIA, has found that patients in neighboring countries can wait over 6 times as long for access to new medicines. The study shows the average time to patient access to treatments across EU and European Economic Area (EEA) countries continues to be as long as 504 days, ranging from 127 days in Germany to over 823 days in Poland. EFPIA HOMEPAGECOVID-19 CHEVRON_RIGHTMANIFESTOCONTACT USKMS LOGINPATIENT ORGANISATIONSPATIENT STORIES EFPIA response to the EU Communication on “Urgent Trade Policy Responses to the COVID-19 crisis" Compulsory licensing will not facilitate greater vaccine equity but could put the hard-won progress in fighting this terrible disease in jeopardy. EFPIA PATIENTS W.A.I.T. INDICATOR 2020 SURVEY 4 Full methodology and definitions by country are available within the appendix Study summary * The Patients W.A.I.T. Indicator is not a measurement of the delays as defined in the “Transparency” Directive (directive 89/105/EEC).Delays under the “Transparency” Directive reflect the EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world through DISCLOSURE OF PAYMENTS TO HCPS Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis for collaboration in thefuture.
IQVIA/EFPIA PIPELINE REVIEW 2021 IQVIA/EFPIA Pipeline Review 2021. This document contains a pipeline overview, deep dives of the eight areas, as well as considerations forinnovation access
ACCELERATING ADOPTION OF COMPLEX CLINICAL TRIALS IN EUROPE Accelerating Adoption of Complex Clinical Trials in Europe and beyond. A multi-stakeholder workshop to develop shared solutions for the use of complex clinical trials to optimise drug development in Europe EFPIA PATIENTS W.A.I.T. INDICATOR 2019 SURVEY The yearly EFPIA Patients WAIT survey, developed with the support of IQVIA, has found that patients in neighboring countries can wait over 6 times as long for access to new medicines. The study shows the average time to patient access to treatments across EU and European Economic Area (EEA) countries continues to be as long as 504 days, ranging from 127 days in Germany to over 823 days in Poland. UNLOCKING THE POWER OF HEALTH DATA: THE PROMISE OF THE Data helps us to make better decisions about how to predict, prevent and treat diseases. The European Health Data Space (EHDS) has the potential to build the foundation for a trustworthy health data ecosystem which will enable better measurement of health outcomes, empower citizens, and create capabilities for the reuse of data for research and development. UNLOCKING THE POTENTIAL OF PRECISION MEDICINE IN EUROPE Advances in biomarker testing are having a transformative impact on cancer care, but Europe will have to overcome significant barriers in the equitable access and quality of these tests to realise their full potential, concludes an important new study released by the International Quality Network for Pathology (IQN Path), the European Cancer Patient Coalition (ECPC) and the European Federation ADDRESSING HEALTHCARE CHALLENGES: NOVEL PRICING AND 5 New challenges and opportunities in healthcare Novel treatments as a result of significant scientific advances—particularly theincreasing
EFPIA HOMEPAGECOVID-19 CHEVRON_RIGHTMANIFESTOCONTACT USKMS LOGINPATIENT ORGANISATIONSPATIENT STORIES EFPIA response to the EU Communication on “Urgent Trade Policy Responses to the COVID-19 crisis" Compulsory licensing will not facilitate greater vaccine equity but could put the hard-won progress in fighting this terrible disease in jeopardy. EFPIA PATIENTS W.A.I.T. INDICATOR 2020 SURVEY 4 Full methodology and definitions by country are available within the appendix Study summary * The Patients W.A.I.T. Indicator is not a measurement of the delays as defined in the “Transparency” Directive (directive 89/105/EEC).Delays under the “Transparency” Directive reflect the EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world through DISCLOSURE OF PAYMENTS TO HCPS Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis for collaboration in thefuture.
IQVIA/EFPIA PIPELINE REVIEW 2021 IQVIA/EFPIA Pipeline Review 2021. This document contains a pipeline overview, deep dives of the eight areas, as well as considerations forinnovation access
ACCELERATING ADOPTION OF COMPLEX CLINICAL TRIALS IN EUROPE Accelerating Adoption of Complex Clinical Trials in Europe and beyond. A multi-stakeholder workshop to develop shared solutions for the use of complex clinical trials to optimise drug development in Europe EFPIA PATIENTS W.A.I.T. INDICATOR 2019 SURVEY The yearly EFPIA Patients WAIT survey, developed with the support of IQVIA, has found that patients in neighboring countries can wait over 6 times as long for access to new medicines. The study shows the average time to patient access to treatments across EU and European Economic Area (EEA) countries continues to be as long as 504 days, ranging from 127 days in Germany to over 823 days in Poland. UNLOCKING THE POWER OF HEALTH DATA: THE PROMISE OF THE Data helps us to make better decisions about how to predict, prevent and treat diseases. The European Health Data Space (EHDS) has the potential to build the foundation for a trustworthy health data ecosystem which will enable better measurement of health outcomes, empower citizens, and create capabilities for the reuse of data for research and development. UNLOCKING THE POTENTIAL OF PRECISION MEDICINE IN EUROPE Advances in biomarker testing are having a transformative impact on cancer care, but Europe will have to overcome significant barriers in the equitable access and quality of these tests to realise their full potential, concludes an important new study released by the International Quality Network for Pathology (IQN Path), the European Cancer Patient Coalition (ECPC) and the European Federation ADDRESSING HEALTHCARE CHALLENGES: NOVEL PRICING AND 5 New challenges and opportunities in healthcare Novel treatments as a result of significant scientific advances—particularly theincreasing
THE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical PATIENT ORGANISATIONS Meaningful Patient engagement is a priority for EFPIA. In 2019, the EFPIA board endorsed the patient engagement strategy focused on enhancing EFPIA’s patient-centricity, helping to advance the field of patient engagement through the EFPIA Patient Think Tank and through multi-stakeholder collaborations, like IMI PARADIGM and for EFPIA to support its members in delivering their own patient THE PHARMACEUTICAL INDUSTRY IN FIGURES EFPIA Key Data | 2020 4 62.3% 10.4% Pharmerging comprises 21 6.5% 18.4 % Pharmerging Japan Europe (Top 5) Rest of the World USA 2.4% MAIN TRENDS The research-based pharmaceutical industry can play a critical role in restoring Europe to growth and NEW ECIPE STUDY ON “INTERNATIONAL EU27 PHARMACEUTICAL New ECIPE study on “International EU27 pharmaceutical production, trade, dependencies and vulnerabilities” Faced with the COVID-19 pandemic, global supply chains have shown remarkable resilience, and open markets and open trade have been one of the key reasons behindthis.
COVID-19 VACCINE MAKERS INVITE G20 LEADERS TO SUPPORT THE Innovative vaccine manufacturers and biotech companies are at the forefront of the global effort to develop and manufacture COVID-19 vaccines. Despite a massive effort to scale up and produce billions of vaccine doses, COVID-19 vaccines currently are not equally reaching all priority populations worldwide. The innovative vaccine manufacturers and biotech companies have supported fair and INTELLECTUAL PROPERTY IP is the key driver of innovation. It has enabled unprecedented collaborations between biopharmaceutical innovators and governments, universities and other research partners to speed up progress on hundreds of potential COVID-19 treatments, diagnostics and vaccinesfor patients.
DISCLOSURE OF PAYMENTS TO HCPS Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis for collaboration in thefuture.
PODCAST: FROM RAW MATERIALS TO PATIENTS’ ARMS Today we're asking Luc Van Steenwinkel, Site Lead, Pfizer Puurs and Vice President Pfizer Biotech Operations, and Danny Hendrikse, Vice President, Pfizer Global Supply Chain, "From raw materials to patients’ arms – how are COVID-19 vaccines made?". Listen to hear their discussion on the challenge and how we're preparing for thefuture.
EU-LEVEL COLLABORATION ON JOINT CLINICAL ASSESSMENT OF COVID-19 has had a significant impact on the functioning of the regular EU institutional decision-making process. In March, the EU institutions moved to an ‘all hands-on deck’ approach to try to mitigate the impact of COVID-19 on healthcare systems across EU member states. There have been some notable successes, especially when it comes to measures to ensure the continuous supply of UNLOCKING THE POTENTIAL OF THE EUROPEAN HEALTH DATA SPACE Managing a public health crisis effectively is not simply about controlling the spread of a virus. For people living with one or multiple chronic diseases, pandemics such as COVID-19 bring severe synergistic impacts, which require a more nuanced and comprehensive approach to how we manage diseases, particularly in times of crises.EFPIA HOMEPAGE
Europe’s framework of incentives and rewards for discovering and developing new treatments deliver access to today’s medicines and investment into tomorrow’s cures for patients who need them. Only 8 OMP medicines existed in 2000, before the EU Regulation came in to force, compared to 184 today. EFPIA PATIENTS W.A.I.T. INDICATOR 2020 SURVEY 4 Full methodology and definitions by country are available within the appendix Study summary * The Patients W.A.I.T. Indicator is not a measurement of the delays as defined in the “Transparency” Directive (directive 89/105/EEC).Delays under the “Transparency” Directive reflect the EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world throughTHE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical DISCLOSURE OF PAYMENTS TO HCPS Disclosure of payments to HCPs. Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis UNLOCKING THE POTENTIAL OF THE EUROPEAN HEALTH DATA SPACE Managing a public health crisis effectively is not simply about controlling the spread of a virus. For people living with one or multiple chronic diseases, pandemics such as COVID-19 bring severe synergistic impacts, which require a more nuanced and comprehensive approach to how we manage diseases, particularly in times of crises. ACCELERATING ADOPTION OF COMPLEX CLINICAL TRIALS IN EUROPE Register. Complex Clinical Trials (CCTs) have the potential to accelerate drug development and enable patients to get timely access to transformative therapies. The main objective of this workshop is to develop shared solutions by: What is CCT – simplifying and standardising definition of CCT. Why CCTs – how CCT can acceleratedrug development.
IQVIA/EFPIA PIPELINE REVIEW 2021 IQVIA/EFPIA Pipeline Review 2021. This document contains a pipeline overview, deep dives of the eight areas, as well as considerations forinnovation access
NATHALIE MOLL
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for UNLOCKING THE POTENTIAL OF PRECISION MEDICINE IN EUROPE Advances in biomarker testing are having a transformative impact on cancer care, but Europe will have to overcome significant barriers in the equitable access and quality of these tests to realise their full potential, concludes an important new study released by the International Quality Network for Pathology (IQN Path), the European Cancer Patient Coalition (ECPC) and the European Federation EFPIA HOMEPAGECOVID-19 CHEVRON_RIGHTMANIFESTOCONTACT USKMS LOGINPATIENT ORGANISATIONSPATIENT STORIES Europe’s framework of incentives and rewards for discovering and developing new treatments deliver access to today’s medicines and investment into tomorrow’s cures for patients who need them. Only 8 OMP medicines existed in 2000, before the EU Regulation came in to force, compared to 184 today. EFPIA PATIENTS W.A.I.T. INDICATOR 2020 SURVEY 4 Full methodology and definitions by country are available within the appendix Study summary * The Patients W.A.I.T. Indicator is not a measurement of the delays as defined in the “Transparency” Directive (directive 89/105/EEC).Delays under the “Transparency” Directive reflect the EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world throughTHE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical DISCLOSURE OF PAYMENTS TO HCPS Disclosure of payments to HCPs. Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis UNLOCKING THE POTENTIAL OF THE EUROPEAN HEALTH DATA SPACE Managing a public health crisis effectively is not simply about controlling the spread of a virus. For people living with one or multiple chronic diseases, pandemics such as COVID-19 bring severe synergistic impacts, which require a more nuanced and comprehensive approach to how we manage diseases, particularly in times of crises. ACCELERATING ADOPTION OF COMPLEX CLINICAL TRIALS IN EUROPE Register. Complex Clinical Trials (CCTs) have the potential to accelerate drug development and enable patients to get timely access to transformative therapies. The main objective of this workshop is to develop shared solutions by: What is CCT – simplifying and standardising definition of CCT. Why CCTs – how CCT can acceleratedrug development.
IQVIA/EFPIA PIPELINE REVIEW 2021 IQVIA/EFPIA Pipeline Review 2021. This document contains a pipeline overview, deep dives of the eight areas, as well as considerations forinnovation access
NATHALIE MOLL
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for UNLOCKING THE POTENTIAL OF PRECISION MEDICINE IN EUROPE Advances in biomarker testing are having a transformative impact on cancer care, but Europe will have to overcome significant barriers in the equitable access and quality of these tests to realise their full potential, concludes an important new study released by the International Quality Network for Pathology (IQN Path), the European Cancer Patient Coalition (ECPC) and the European FederationTHE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical DISCLOSURE OF PAYMENTS TO HCPS Disclosure of payments to HCPs. Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basis NEW ECIPE STUDY ON “INTERNATIONAL EU27 PHARMACEUTICAL New ECIPE study on “International EU27 pharmaceutical production, trade, dependencies and vulnerabilities” Faced with the COVID-19 pandemic, global supply chains have shown remarkable resilience, and open markets and open trade have been one of the key reasons behindthis.
INTELLECTUAL PROPERTY Intellectual property has the power to bring about vital medical innovation. It creates access to new treatments which in turn creates healthy populations. It can support people’s lives and their livelihoods. YouTube. EFPIA. 627 subscribers. PATIENT ORGANISATIONS Patient organisations. People should be at the heart of healthcare. From, prevention and awareness, through research and development, regulatory and Health Technology Assessment (HTA) processes, to service design and outcomes measurement. Patients bring invaluable knowledge and experience of living with a condition, while patient CANCER CARE IN EUROPE: WHERE ARE WE IN 2020? Among the key findings of the Comparator Report on Cancer in Europe 2020, is what looks like a paradox: although more people are being diagnosed with cancer, a smaller proportion of those people appear to be dying from the disease. The report, a comprehensive overview of major cancer trends across Europe, quickly unravels the mystery. EFPIA RESPONSE TO THE EU ROADMAP ON THE “EVALUATION AND Yesterday, EFPIA filed its response to the EU roadmap/IIA on the “Evaluation and revision of the general pharmaceutical legislation” containing proposed priorities for legislative change to equip the regulatory framework to respond quickly to the needs of patients across Europe.Speaking about the response, EFPIA Director General Nathalie Moll said: “The evaluation of the general FINAL CDEG RECOMMENDATION ON USE OF FORM FDA 1572 FOR 1 EFPIA CDEG position paper on the use of Form FDA 1572 for clinical trials performed outside the USA 14 January 2020 The EFPIA Clinical Development Expert Group (CDEG) was made aware that some EU THE PHARMACEUTICAL INDUSTRY IN FIGURES 7 PHARMACEUTICAL INDUSTRY RESEARCH AND DEVELOPMENT IN EUROPE EFPIA 2017 € million € million Austria 294 Belgium 3,508 Bulgaria n.a Croatia 40 Cyprus 85 Czech Rep. 77 Denmark 1,632 Estonia n.a Finland 201 France 4,451 Germany 6,918 Greece 42 Hungary 176 Iceland n.a Ireland 305 Italy 1,530 Latvia n.a Lithuania n.a Malta n.a Netherlands 642 Norway 126 Poland 340 EFPIA PATIENTS W.A.I.T. INDICATOR 2019 SURVEY The yearly EFPIA Patients WAIT survey, developed with the support of IQVIA, has found that patients in neighboring countries can wait over 6 times as long for access to new medicines. The study shows the average time to patient access to treatments across EU and European Economic Area (EEA) countries continues to be as long as 504 days, ranging from 127 days in Germany to over 823 days in Poland. EFPIA HOMEPAGECOVID-19 CHEVRON_RIGHTMANIFESTOCONTACT USKMS LOGINPATIENT ORGANISATIONSPATIENT STORIES Europe’s framework of incentives and rewards for discovering and developing new treatments deliver access to today’s medicines and investment into tomorrow’s cures for patients who need them. Only 8 OMP medicines existed in 2000, before the EU Regulation came in to force, compared to 184 today.THE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical EFPIA PATIENTS W.A.I.T. INDICATOR 2020 SURVEY 4 Full methodology and definitions by country are available within the appendix Study summary * The Patients W.A.I.T. Indicator is not a measurement of the delays as defined in the “Transparency” Directive (directive 89/105/EEC).Delays under the “Transparency” Directive reflect the EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world through INTELLECTUAL PROPERTY Intellectual property has the power to bring about vital medical innovation. It creates access to new treatments which in turn creates healthy populations. It can support people’s lives and their livelihoods. YouTube. EFPIA. 625 subscribers. EFPIA E4ETHICS MERGE WITH THE MEDTECH EUROPE CONFERENCE In the context of their respective broad ethical programs, EFPIA, the European Federation of Pharmaceutical Industries and Associations, and MedTech Europe, the trade association representing the medical technologies industry in Europe, decided to merge the assessments of the EFPIA’s e4ethics platform and MedTech Europe’s Conference Vetting System (CVS). EFPIA RESPONSE TO THE PUBLICATION OF THE EU INDUSTRIAL EFPIA notes the publication of the Industrial Strategy by the European Commission including a reference to the roadmap to the EU Pharmaceutical Strategy, which will be published tomorrow. EFPIA points to the urgent need for the Industrial Strategy and Pharmaceutical strategy to contain the necessary levers to support the innovative European pharmaceutical industry to ensure UNLOCKING THE POWER OF HEALTH DATA: THE PROMISE OF THE Data helps us to make better decisions about how to predict, prevent and treat diseases. The European Health Data Space (EHDS) has the potential to build the foundation for a trustworthy health data ecosystem which will enable better measurement of health outcomes, empower citizens, and create capabilities for the reuse of data for research and development.NATHALIE MOLL
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for ADDRESSING HEALTHCARE CHALLENGES: NOVEL PRICING AND 5 New challenges and opportunities in healthcare Novel treatments as a result of significant scientific advances—particularly theincreasing
EFPIA HOMEPAGECOVID-19 CHEVRON_RIGHTMANIFESTOCONTACT USKMS LOGINPATIENT ORGANISATIONSPATIENT STORIES Europe’s framework of incentives and rewards for discovering and developing new treatments deliver access to today’s medicines and investment into tomorrow’s cures for patients who need them. Only 8 OMP medicines existed in 2000, before the EU Regulation came in to force, compared to 184 today.THE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical EFPIA PATIENTS W.A.I.T. INDICATOR 2020 SURVEY 4 Full methodology and definitions by country are available within the appendix Study summary * The Patients W.A.I.T. Indicator is not a measurement of the delays as defined in the “Transparency” Directive (directive 89/105/EEC).Delays under the “Transparency” Directive reflect the EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world through INTELLECTUAL PROPERTY Intellectual property has the power to bring about vital medical innovation. It creates access to new treatments which in turn creates healthy populations. It can support people’s lives and their livelihoods. YouTube. EFPIA. 625 subscribers. EFPIA E4ETHICS MERGE WITH THE MEDTECH EUROPE CONFERENCE In the context of their respective broad ethical programs, EFPIA, the European Federation of Pharmaceutical Industries and Associations, and MedTech Europe, the trade association representing the medical technologies industry in Europe, decided to merge the assessments of the EFPIA’s e4ethics platform and MedTech Europe’s Conference Vetting System (CVS). EFPIA RESPONSE TO THE PUBLICATION OF THE EU INDUSTRIAL EFPIA notes the publication of the Industrial Strategy by the European Commission including a reference to the roadmap to the EU Pharmaceutical Strategy, which will be published tomorrow. EFPIA points to the urgent need for the Industrial Strategy and Pharmaceutical strategy to contain the necessary levers to support the innovative European pharmaceutical industry to ensure UNLOCKING THE POWER OF HEALTH DATA: THE PROMISE OF THE Data helps us to make better decisions about how to predict, prevent and treat diseases. The European Health Data Space (EHDS) has the potential to build the foundation for a trustworthy health data ecosystem which will enable better measurement of health outcomes, empower citizens, and create capabilities for the reuse of data for research and development.NATHALIE MOLL
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for ADDRESSING HEALTHCARE CHALLENGES: NOVEL PRICING AND 5 New challenges and opportunities in healthcare Novel treatments as a result of significant scientific advances—particularly theincreasing
THE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical EFPIA RESPONSE ON THE EU COMMUNICATION ON “URGENT TRADE EFPIA and Vaccines Europe notes the EU Communication on “Urgent Trade Policy Responses to the COVID-19 crisis", submitted today to the World Trade Organization (WTO). Speaking about its publication, EFPIA Director General Nathalie Moll said. “While welcoming the commitment to limit export restrictions and facilitate trade, as well as encourage the expansion of vaccine and EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world throughVALUE OF MEDICINES
Medicines and vaccines are some of the most powerful tools in helping people all over Europe are living longer, healthier and more productive lives. Since the 1980’s we have seen death rates from HIV fall by over 80%, since the 1990’s death from cancer have fallen by 20% and recent pharmaceutical innovation means 90% of people living with Hepatitis C can be cured through a 12 week course PATIENT ORGANISATIONS Patient organisations. People should be at the heart of healthcare. From, prevention and awareness, through research and development, regulatory and Health Technology Assessment (HTA) processes, to service design and outcomes measurement. Patients bring invaluable knowledge and experience of living with a condition, while patient INTELLECTUAL PROPERTY Intellectual property has the power to bring about vital medical innovation. It creates access to new treatments which in turn creates healthy populations. It can support people’s lives and their livelihoods. YouTube. EFPIA. 625 subscribers. DISCLOSURE OF PAYMENTS TO HCPS Disclosure of payments to HCPs. Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basisEFPIA - NEWSLETTER
About the EFPIA newsletter. The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe.WEWON'TREST
Illness can be relentless. But #WeWontRest in our quest to discover and develop new medicines for patients in Europe. It is what keeps us up at night. It is what drives us. And with over 7,000 new medicines in development, #WeWontRest until we’ve helped make Europe a healthier place for everyone. EFPIA PATIENTS W.A.I.T. INDICATOR 2019 SURVEY The yearly EFPIA Patients WAIT survey, developed with the support of IQVIA, has found that patients in neighboring countries can wait over 6 times as long for access to new medicines. The study shows the average time to patient access to treatments across EU and European Economic Area (EEA) countries continues to be as long as 504 days, ranging from 127 days in Germany to over 823 days in Poland. EFPIA HOMEPAGECOVID-19 CHEVRON_RIGHTMANIFESTOCONTACT USKMS LOGINPATIENT ORGANISATIONSPATIENT STORIES Europe’s framework of incentives and rewards for discovering and developing new treatments deliver access to today’s medicines and investment into tomorrow’s cures for patients who need them. Only 8 OMP medicines existed in 2000, before the EU Regulation came in to force, compared to 184 today. EFPIA PATIENTS W.A.I.T. INDICATOR 2020 SURVEY 4 Full methodology and definitions by country are available within the appendix Study summary * The Patients W.A.I.T. Indicator is not a measurement of the delays as defined in the “Transparency” Directive (directive 89/105/EEC).Delays under the “Transparency” Directive reflect theTHE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world through INTELLECTUAL PROPERTY Intellectual property has the power to bring about vital medical innovation. It creates access to new treatments which in turn creates healthy populations. It can support people’s lives and their livelihoods. YouTube. EFPIA. 625 subscribers. EFPIA E4ETHICS MERGE WITH THE MEDTECH EUROPE CONFERENCE In the context of their respective broad ethical programs, EFPIA, the European Federation of Pharmaceutical Industries and Associations, and MedTech Europe, the trade association representing the medical technologies industry in Europe, decided to merge the assessments of the EFPIA’s e4ethics platform and MedTech Europe’s Conference Vetting System (CVS). EFPIA RESPONSE TO THE PUBLICATION OF THE EU INDUSTRIAL EFPIA notes the publication of the Industrial Strategy by the European Commission including a reference to the roadmap to the EU Pharmaceutical Strategy, which will be published tomorrow. EFPIA points to the urgent need for the Industrial Strategy and Pharmaceutical strategy to contain the necessary levers to support the innovative European pharmaceutical industry to ensure UNLOCKING THE POWER OF HEALTH DATA: THE PROMISE OF THE Data helps us to make better decisions about how to predict, prevent and treat diseases. The European Health Data Space (EHDS) has the potential to build the foundation for a trustworthy health data ecosystem which will enable better measurement of health outcomes, empower citizens, and create capabilities for the reuse of data for research and development.NATHALIE MOLL
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for ADDRESSING HEALTHCARE CHALLENGES: NOVEL PRICING AND 5 New challenges and opportunities in healthcare Novel treatments as a result of significant scientific advances—particularly theincreasing
EFPIA HOMEPAGECOVID-19 CHEVRON_RIGHTMANIFESTOCONTACT USKMS LOGINPATIENT ORGANISATIONSPATIENT STORIES Europe’s framework of incentives and rewards for discovering and developing new treatments deliver access to today’s medicines and investment into tomorrow’s cures for patients who need them. Only 8 OMP medicines existed in 2000, before the EU Regulation came in to force, compared to 184 today.THE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical EFPIA PATIENTS W.A.I.T. INDICATOR 2020 SURVEY 4 Full methodology and definitions by country are available within the appendix Study summary * The Patients W.A.I.T. Indicator is not a measurement of the delays as defined in the “Transparency” Directive (directive 89/105/EEC).Delays under the “Transparency” Directive reflect the EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world through INTELLECTUAL PROPERTY Intellectual property has the power to bring about vital medical innovation. It creates access to new treatments which in turn creates healthy populations. It can support people’s lives and their livelihoods. YouTube. EFPIA. 625 subscribers. EFPIA E4ETHICS MERGE WITH THE MEDTECH EUROPE CONFERENCE In the context of their respective broad ethical programs, EFPIA, the European Federation of Pharmaceutical Industries and Associations, and MedTech Europe, the trade association representing the medical technologies industry in Europe, decided to merge the assessments of the EFPIA’s e4ethics platform and MedTech Europe’s Conference Vetting System (CVS). EFPIA RESPONSE TO THE PUBLICATION OF THE EU INDUSTRIAL EFPIA notes the publication of the Industrial Strategy by the European Commission including a reference to the roadmap to the EU Pharmaceutical Strategy, which will be published tomorrow. EFPIA points to the urgent need for the Industrial Strategy and Pharmaceutical strategy to contain the necessary levers to support the innovative European pharmaceutical industry to ensure UNLOCKING THE POWER OF HEALTH DATA: THE PROMISE OF THE Data helps us to make better decisions about how to predict, prevent and treat diseases. The European Health Data Space (EHDS) has the potential to build the foundation for a trustworthy health data ecosystem which will enable better measurement of health outcomes, empower citizens, and create capabilities for the reuse of data for research and development.NATHALIE MOLL
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for ADDRESSING HEALTHCARE CHALLENGES: NOVEL PRICING AND 5 New challenges and opportunities in healthcare Novel treatments as a result of significant scientific advances—particularly theincreasing
THE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical EFPIA RESPONSE ON THE EU COMMUNICATION ON “URGENT TRADE EFPIA and Vaccines Europe notes the EU Communication on “Urgent Trade Policy Responses to the COVID-19 crisis", submitted today to the World Trade Organization (WTO). Speaking about its publication, EFPIA Director General Nathalie Moll said. “While welcoming the commitment to limit export restrictions and facilitate trade, as well as encourage the expansion of vaccine and EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world throughVALUE OF MEDICINES
Medicines and vaccines are some of the most powerful tools in helping people all over Europe are living longer, healthier and more productive lives. Since the 1980’s we have seen death rates from HIV fall by over 80%, since the 1990’s death from cancer have fallen by 20% and recent pharmaceutical innovation means 90% of people living with Hepatitis C can be cured through a 12 week course PATIENT ORGANISATIONS Patient organisations. People should be at the heart of healthcare. From, prevention and awareness, through research and development, regulatory and Health Technology Assessment (HTA) processes, to service design and outcomes measurement. Patients bring invaluable knowledge and experience of living with a condition, while patient INTELLECTUAL PROPERTY Intellectual property has the power to bring about vital medical innovation. It creates access to new treatments which in turn creates healthy populations. It can support people’s lives and their livelihoods. YouTube. EFPIA. 625 subscribers. DISCLOSURE OF PAYMENTS TO HCPS Disclosure of payments to HCPs. Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basisEFPIA - NEWSLETTER
About the EFPIA newsletter. The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe.WEWON'TREST
Illness can be relentless. But #WeWontRest in our quest to discover and develop new medicines for patients in Europe. It is what keeps us up at night. It is what drives us. And with over 7,000 new medicines in development, #WeWontRest until we’ve helped make Europe a healthier place for everyone. EFPIA PATIENTS W.A.I.T. INDICATOR 2019 SURVEY The yearly EFPIA Patients WAIT survey, developed with the support of IQVIA, has found that patients in neighboring countries can wait over 6 times as long for access to new medicines. The study shows the average time to patient access to treatments across EU and European Economic Area (EEA) countries continues to be as long as 504 days, ranging from 127 days in Germany to over 823 days in Poland. EFPIA HOMEPAGECOVID-19 CHEVRON_RIGHTMANIFESTOCONTACT USKMS LOGINPATIENT ORGANISATIONSPATIENT STORIES Europe’s framework of incentives and rewards for discovering and developing new treatments deliver access to today’s medicines and investment into tomorrow’s cures for patients who need them. Only 8 OMP medicines existed in 2000, before the EU Regulation came in to force, compared to 184 today. EFPIA PATIENTS W.A.I.T. INDICATOR 2020 SURVEY 4 Full methodology and definitions by country are available within the appendix Study summary * The Patients W.A.I.T. Indicator is not a measurement of the delays as defined in the “Transparency” Directive (directive 89/105/EEC).Delays under the “Transparency” Directive reflect the THE EFPIA CODEEFPIA CODE OF CONDUCTEFPIA DISCLOSURE CODEEFPIA PHARMA GUIDELINESEFPIA MEMBER COUNTRIESEFPIA MEMBERSEFPIA TRANSPARENCY CODE The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world through INTELLECTUAL PROPERTY Intellectual property has the power to bring about vital medical innovation. It creates access to new treatments which in turn creates healthy populations. It can support people’s lives and their livelihoods. YouTube. EFPIA. 625 subscribers. EFPIA E4ETHICS MERGE WITH THE MEDTECH EUROPE CONFERENCE In the context of their respective broad ethical programs, EFPIA, the European Federation of Pharmaceutical Industries and Associations, and MedTech Europe, the trade association representing the medical technologies industry in Europe, decided to merge the assessments of the EFPIA’s e4ethics platform and MedTech Europe’s Conference Vetting System (CVS). EFPIA RESPONSE TO THE PUBLICATION OF THE EU INDUSTRIAL EFPIA notes the publication of the Industrial Strategy by the European Commission including a reference to the roadmap to the EU Pharmaceutical Strategy, which will be published tomorrow. EFPIA points to the urgent need for the Industrial Strategy and Pharmaceutical strategy to contain the necessary levers to support the innovative European pharmaceutical industry to ensure UNLOCKING THE POWER OF HEALTH DATA: THE PROMISE OF THE Data helps us to make better decisions about how to predict, prevent and treat diseases. The European Health Data Space (EHDS) has the potential to build the foundation for a trustworthy health data ecosystem which will enable better measurement of health outcomes, empower citizens, and create capabilities for the reuse of data for research and development.NATHALIE MOLL
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for ADDRESSING HEALTHCARE CHALLENGES: NOVEL PRICING AND 5 New challenges and opportunities in healthcare Novel treatments as a result of significant scientific advances—particularly theincreasing
EFPIA HOMEPAGECOVID-19 CHEVRON_RIGHTMANIFESTOCONTACT USKMS LOGINPATIENT ORGANISATIONSPATIENT STORIES Europe’s framework of incentives and rewards for discovering and developing new treatments deliver access to today’s medicines and investment into tomorrow’s cures for patients who need them. Only 8 OMP medicines existed in 2000, before the EU Regulation came in to force, compared to 184 today. EFPIA PATIENTS W.A.I.T. INDICATOR 2020 SURVEY 4 Full methodology and definitions by country are available within the appendix Study summary * The Patients W.A.I.T. Indicator is not a measurement of the delays as defined in the “Transparency” Directive (directive 89/105/EEC).Delays under the “Transparency” Directive reflect the THE EFPIA CODEEFPIA CODE OF CONDUCTEFPIA DISCLOSURE CODEEFPIA PHARMA GUIDELINESEFPIA MEMBER COUNTRIESEFPIA MEMBERSEFPIA TRANSPARENCY CODE The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world through INTELLECTUAL PROPERTY Intellectual property has the power to bring about vital medical innovation. It creates access to new treatments which in turn creates healthy populations. It can support people’s lives and their livelihoods. YouTube. EFPIA. 625 subscribers. EFPIA E4ETHICS MERGE WITH THE MEDTECH EUROPE CONFERENCE In the context of their respective broad ethical programs, EFPIA, the European Federation of Pharmaceutical Industries and Associations, and MedTech Europe, the trade association representing the medical technologies industry in Europe, decided to merge the assessments of the EFPIA’s e4ethics platform and MedTech Europe’s Conference Vetting System (CVS). EFPIA RESPONSE TO THE PUBLICATION OF THE EU INDUSTRIAL EFPIA notes the publication of the Industrial Strategy by the European Commission including a reference to the roadmap to the EU Pharmaceutical Strategy, which will be published tomorrow. EFPIA points to the urgent need for the Industrial Strategy and Pharmaceutical strategy to contain the necessary levers to support the innovative European pharmaceutical industry to ensure UNLOCKING THE POWER OF HEALTH DATA: THE PROMISE OF THE Data helps us to make better decisions about how to predict, prevent and treat diseases. The European Health Data Space (EHDS) has the potential to build the foundation for a trustworthy health data ecosystem which will enable better measurement of health outcomes, empower citizens, and create capabilities for the reuse of data for research and development.NATHALIE MOLL
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for ADDRESSING HEALTHCARE CHALLENGES: NOVEL PRICING AND 5 New challenges and opportunities in healthcare Novel treatments as a result of significant scientific advances—particularly theincreasing
THE EFPIA CODE
The EFPIA Code of Practice The EFPIA Code constitutes the collection of ethical rules agreed by EFPIA members for the Promotion of Medicinal Products to healthcare professionals (HCPs) and the interactions with HCPs, healthcare organisations (HCOs) and patients' organisations (POs), with the intent of guaranteeing that these activities are conducted while respecting the most stringent ethical EFPIA RESPONSE ON THE EU COMMUNICATION ON “URGENT TRADE EFPIA and Vaccines Europe notes the EU Communication on “Urgent Trade Policy Responses to the COVID-19 crisis", submitted today to the World Trade Organization (WTO). Speaking about its publication, EFPIA Director General Nathalie Moll said. “While welcoming the commitment to limit export restrictions and facilitate trade, as well as encourage the expansion of vaccine and EFPIA STATEMENT ON IP WAIVER FOR COVID-19 VACCINES Speaking about the US administration’s decision to support a proposal to waive patents on COVID-19 vaccines, EFPIA Director General Nathalie Moll said. “This short-sighted and ineffectual decision by the Biden administration puts the hard-won progress in fighting this terrible disease in jeopardy. While we wholeheartedly agree with the goal of protecting citizens around the world throughVALUE OF MEDICINES
Medicines and vaccines are some of the most powerful tools in helping people all over Europe are living longer, healthier and more productive lives. Since the 1980’s we have seen death rates from HIV fall by over 80%, since the 1990’s death from cancer have fallen by 20% and recent pharmaceutical innovation means 90% of people living with Hepatitis C can be cured through a 12 week course PATIENT ORGANISATIONS Patient organisations. People should be at the heart of healthcare. From, prevention and awareness, through research and development, regulatory and Health Technology Assessment (HTA) processes, to service design and outcomes measurement. Patients bring invaluable knowledge and experience of living with a condition, while patient INTELLECTUAL PROPERTY Intellectual property has the power to bring about vital medical innovation. It creates access to new treatments which in turn creates healthy populations. It can support people’s lives and their livelihoods. YouTube. EFPIA. 625 subscribers. DISCLOSURE OF PAYMENTS TO HCPS Disclosure of payments to HCPs. Under the EFPIA Code, the pharmaceutical industry have to disclose payments made to healthcare professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. Bringing greater transparency to this, already well-regulated, vital relationship is about strengthening the basisEFPIA - NEWSLETTER
About the EFPIA newsletter. The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe.WEWON'TREST
Illness can be relentless. But #WeWontRest in our quest to discover and develop new medicines for patients in Europe. It is what keeps us up at night. It is what drives us. And with over 7,000 new medicines in development, #WeWontRest until we’ve helped make Europe a healthier place for everyone. EFPIA PATIENTS W.A.I.T. INDICATOR 2019 SURVEY The yearly EFPIA Patients WAIT survey, developed with the support of IQVIA, has found that patients in neighboring countries can wait over 6 times as long for access to new medicines. The study shows the average time to patient access to treatments across EU and European Economic Area (EEA) countries continues to be as long as 504 days, ranging from 127 days in Germany to over 823 days in Poland. This website uses cookies to offer you a better browsing experience. If you continue browsing our website, you accept these cookies. Find out more on how we use cookies and how you can change your settings.Read Cookie Policy_done_ Agree
_clear_
_close_
*
__
Home
*
__
COVID-19 _chevron_right_*
__
#WE-WONT-REST _chevron_right_*
__
News & Events _chevron_right_*
__
Manifesto
*
__
About medicines _chevron_right_*
__
Relationships & code _chevron_right_*
__
Publications _chevron_right_*
__
About us _chevron_right_*
__
Contact us
*
__
KMS Login
_ arrow_back_ _close_* __ COVID-19
*
__ Member Updates
*
__ News
* __ #WE-WONT-REST
*
__ Illness Never Sleeps*
__ Brighter Tomorrow*
__ For the Chance
*
__ Questions Inspire Solutions*
__ Pledge Wall
*
__ Patient stories
*
__ Innovation _expand_more_ _expand_less_ _chevron_right_*
__ Diabetes
*
__ Alzheimer’s disease*
__ Migraine
*
__ Blood cancers
*
__ Lung cancer
*
__ NASH
*
__ Antibacterial Monoclonal Antibodies*
__ Haemophilia
*
__ C.difficile
* __ News & Events
*
__ The EFPIA View
*
__ Events
*
__ Newsletter
* __ Manifesto
* __ About medicines*
__ Development of medicines _expand_more_ _expand_less__chevron_right_
*
__ Public-private partnerships*
__ Animal Use and Welfare*
__ Regulations, safety & supply*
__ Intellectual Property*
__ Trade
*
__ Digital Health
*
__ SMEs in Europe
*
__ Use of medicines _expand_more_ _expand_less_ _chevron_right_*
__ Value of medicines*
__ HTA & Relative Efficacy Assessment*
__ Outcomes-focused, sustainable healthcare*
__ Disease-specific groups * __ Relationships & code*
__ The EFPIA Code
*
__ Patient organisations*
__ Healthcare professionals (HCPs)*
__ Disclosure of payments to HCPs*
__ National codes
*
__ EU institutions
* __ Publications
*
__ Data center
*
__ Downloads
*
__ Cancer Comparator Report _expand_more_ _expand_less__chevron_right_
*
__ About
*
__ Recommendations
*
__ Cancer Cases
*
__ Cancer Deaths
*
__ Survival
*
__ Cancer Care
*
__ Cancer Types
*
__ Resources
* __ About us
*
__ Who we are
*
__ EFPIA Japan
*
__ Membership
*
__ Job vacancies
* __ Contact us
_ arrow_back_ _close_* __ Innovation
*
__ Diabetes
*
__ Alzheimer’s disease*
__ Migraine
*
__ Blood cancers
*
__ Lung cancer
*
__ NASH
*
__ Antibacterial Monoclonal Antibodies*
__ Haemophilia
*
__ C.difficile
* __ Development of medicines*
__ Public-private partnerships*
__ Animal Use and Welfare*
__ Regulations, safety & supply*
__ Intellectual Property*
__ Trade
*
__ Digital Health
*
__ SMEs in Europe
* __ Use of medicines*
__ Value of medicines*
__ HTA & Relative Efficacy Assessment*
__ Outcomes-focused, sustainable healthcare*
__ Disease-specific groups * __ Cancer Comparator Report*
__ About
*
__ Recommendations
*
__ Cancer Cases
*
__ Cancer Deaths
*
__ Survival
*
__ Cancer Care
*
__ Cancer Types
*
__ Resources
__
_close_
TACKLING COVID-19
AS WE STAY APART, PHARMACEUTICAL COMPANIES ARE COMING TOGETHER TO FIGHT AGAINST COVID-19LEARN MORE
Intellectual Property Europe’s framework of incentives and rewards for discovering and developing new treatments deliver access to today’s medicines and investment into tomorrow’s cures for patients who need them. LEARNMORE
Help us make rare disease even rarer Only 8 OMP medicines existed in 2000, before the EU Regulation came in to force, compared to 184 today. LEARN MORE Relationships and Code EFPIA Code of Practice and relationships with patient organisations and healthcare professionals LEARN MORELATEST UPDATES
VIEW ALL
*
Statements & press releases 04.06.21 EFPIA RESPONSE TO THE EU COMMUNICATION ON “URGENT TRADE POLICY RESPONSES TO THE COVID-19 CRISIS" Compulsory licensing will not facilitate greater vaccine equity but could put the hard-won progress in fighting this terrible disease injeopardy.
Read Article
*
Blog articles 31.05.21 PODCAST: HOW IS THE PHARMACEUTICAL INDUSTRY CONTRIBUTING TO A HEALTHYENVIRONMENT?
Welcome to 19 ConversationsRead Article
*
Blog articles 27.05.21 INDUSTRY AS A PARTNER TO STRENGTHEN HEALTHCARE SYSTEMS AFTER COVID-19(GUEST BLOG)
Catherine Owen, Head of Major Markets at Bristol Myers Squibb, discusses how the pharmaceutical industry has supported healthcare systems to overcome the...Read Article
*
EFPIA Events 29.06.21 HOW CAN COVID-19 TREATMENTS HELP US ON THE ROAD TO RECOVERY? An EFPIA virtual eventView Event
*
External Events 22.08.21 11TH WORLD CONGRESS ON ALTERNATIVES AND ANIMAL USE IN THE LIFESCIENCES 2020
The Congress will explore the latest in 3R R&D and will provide a multidisciplinary programme covering more traditional themes as well as very latest issues...View Event
*
External Events 07.09.21 DIA PHARMACOVIGILANCE STRATEGIES WORKSHOP A unique opportunity to engage in the sharing of good practices between industry representatives and seek the advice you need fromregulators.
View Event
FEATURED ARTICLES
FEATURED EVENT
EVERY DAY COUNTS
Accelerate access. Beat cancer.View Event
*
*
*
*
*
EFPIA 2021 All rights reserved Privacy Policy__ __
__
__
__
*
*
*
*
*
__ __
__
__
__
EFPIA 2016 All rights reservedDisclaimer
close
continue
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0